Symbiotec Pharmalab share price
NSE: SYMBIOTECBSE: 544889Pharmaceuticals & Biotechnology
Symbiotec Pharmalab Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2026 · Issue price ₹988
Last close ₹1,274.70down ₹3.10 (0.24%)BSE ₹1,274.00
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,277.80.
28 Oct: open ₹1,285.90, high ₹1,294.40, low ₹1,248.00
Range of traded prices from listing on 1 Sep 2026 to 28 Oct 2026
₹934.20Low, 1 Sep 2026₹1,309.90High, 16 Oct 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹8,191 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No balance sheet
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Sep 2026
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,50,41834.4% delivered
Results
Consolidated; ₹ crore; no annual accounts on record yet.Symbiotec Pharmalab quarterly results
Quarter to Jun 2026
- Revenue
- ₹218 Cr
- Net profit
- ₹14 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.4%
| ₹ crore | Jun 2026 |
|---|---|
| Revenue | 218 |
| Net profit | 14 |
| Net margin | 6.4% |
Consolidated. The quarter to Jun 2026, the first on record. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the quarter to Jun 2026 the company reports one business segment, Manfucaturing of Pharmaceutical, which carries all its revenue.
Mutual fund holdings
35 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.All 35 funds holding Symbiotec Pharmalab
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- AddedAdded. Funds that held more shares than at the end of the month before.
- 17
- CutCut. Funds that held fewer shares than at the end of the month before.
- 2
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 9
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 25
| Fund | |||
|---|---|---|---|
 Motilal Oswal Small Cap FundMotilal Oswal Mutual Fund | 9,29,089 | 1.32% | ₹109.3 Cr |
 ICICI Prudential Small Cap FundICICI Prudential Mutual Fund | 8,07,290 | 0.97% | ₹95.0 Cr |
 Mirae Asset Aggressive Hybrid FundMirae Asset Mutual Fund | 7,73,462 | 0.99% | ₹91.0 Cr |
| Mirae Asset Midcap FundMirae Asset Mutual Fund | 7,40,752 | 0.45% | ₹87.2 Cr |
| Mirae Asset Multicap FundMirae Asset Mutual Fund | 5,50,000 | 1.20% | ₹64.7 Cr |
| Mirae Asset ELSS Tax Saver FundMirae Asset Mutual Fund | 5,47,602 | 0.26% | ₹64.4 Cr |
| Mirae Asset Small Cap FundMirae Asset Mutual Fund | 4,94,818 | 1.00% | ₹58.2 Cr |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 4,74,270 | 1.60% | ₹55.8 Cr |
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 4,04,865 | 1.36% | ₹47.6 Cr |
 Mahindra Manulife Small Cap FundMahindra Manulife Mutual Fund | 2,53,050 | 0.55% | ₹29.8 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Symbiotec Pharmalab insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others0 purchases, 16 salesNo purchase₹12 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹12 Cr5 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Symbiotec Pharmalab competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Symbiotec Pharmalab in market cap.Healthcare companies
Symbiotec Pharmalab is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Viyash ScientificVIYASH | 10,025 | – | 3.44 | +96.5% | – | – | 11.2% | 0.00% |
 Strides Pharma ScienceSTAR | 10,006 | 16.31 | 3.22 | +7.3% | – | 21.7% | 15.1% | 0.46% |
 Blue Jet HealthcareBLUEJET | 9,802 | 41.73 | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.23% |
 Procter & Gamble HealthPGHL | 8,962 | 25.11 | 17.09 | – | – | 67.2% | 84.2% | 3.80% |
 Aarti PharmalabsAARTIPHARM | 7,998 | – | 3.55 | +13.4% | – | – | 11.9% | 0.40% |
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,653 | 27.36 | 22.00 | +22.7% | +28.4% | 92.5% | 102.5% | 2.26% |
 Supriya LifescienceSUPRIYA | 6,940 | 34.98 | 5.79 | +28.1% | +11.4% | 18.1% | 21.6% | 0.12% |
 Bliss GVS PharmaBLISSGVS | 6,896 | 50.63 | 5.78 | +20.6% | +27.7% | 12.1% | 12.3% | 0.23% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Symbiotec Pharmalab announcements
Oct 2026
28 Oct · Analysts
Sep 2026
30 Sep
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,229.80 | 1,282.20 | 1,223.00 | 1,277.80 | 1,262.25 | 4,21,215 | 38.9% |
| 26 Oct 2026 | 1,162.10 | 1,250.10 | 1,160.00 | 1,229.80 | 1,218.83 | 7,27,128 | 37.6% |
| 23 Oct 2026 | 1,197.50 | 1,197.50 | 1,153.50 | 1,164.20 | 1,170.38 | 2,58,232 | 31.5% |
| 22 Oct 2026 | 1,194.10 | 1,218.20 | 1,168.10 | 1,197.50 | 1,193.26 | 2,97,702 | 30.2% |
| 21 Oct 2026 | 1,240.00 | 1,246.50 | 1,187.00 | 1,208.40 | 1,208.04 | 4,31,881 | 40.1% |
| 19 Oct 2026 | 1,268.10 | 1,286.80 | 1,223.30 | 1,238.60 | 1,261.28 | 5,10,021 | 41.1% |
| 16 Oct 2026 | 1,253.00 | 1,309.90 | 1,235.00 | 1,279.50 | 1,280.16 | 10,06,476 | 39.6% |
| 15 Oct 2026 | 1,256.00 | 1,308.00 | 1,233.70 | 1,254.90 | 1,273.25 | 21,09,252 | 31.7% |
| 14 Oct 2026 | 1,175.00 | 1,284.50 | 1,170.10 | 1,253.20 | 1,242.91 | 24,73,759 | 32.3% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SYMBIOTEC
- BSE code
- 544889
- ISIN
- INE899I01028
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.symbiotec.com
- CIN
- U24232MP2002PLC015293
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2002
- Registered office
- 385/2, PigdamberRau, Mhow, Indore 453331, Madhya Pradesh
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments